Table 1.
Overview of clinical trials investigating drugs with ECM remodeling properties in combination with nano-formulations for cancer therapy, as of July 17 2019
| ECM remodeling drug | Design | Cancer type | Clinical Phase | Clinicaltrials.gov identifier | |
|---|---|---|---|---|---|
| Liposomal Irinotecan, Onivyde ® | |||||
| Paricalcitol | Liposomal Irinotecan + 5-FU + Leucovorin + Paricalcitol | Pancreatic cancer | 1 | NCT03883919 | |
| Protein-bound paclitaxel, Nab-Paclitaxel (nanoparticle albumin-bound paclitaxel), Abraxane® | |||||
| PEGPH20 (PEGylated hyaluronidase) |
PEGPH20 + Nab-paclitaxel + Gemcitabine VS Nab-paclitaxel + Gemcitabine | Pancreatic cancer | 2 | NCT01839487 | |
| PEGPH20 + Nab-paclitaxel + Gemcitabine + Rivaroxaban | Pancreatic cancer | N/A | NCT02921022 | ||
| PEGPH20 + Nab-Paclitaxel + Gemcitabine VS Placebo + Nab-Paclitaxel + Gemcitabine | Pancreatic cancer | 3 | NCT02715804 | ||
| PEGPH20 monotherapy followed by combination therapy of PEGPH20 + Nab-Paclitaxel + Gemcitabine | Pancreatic cancer | 2 | NCT02487277 | ||
| Paricalcitol | Paricalcitol IV + Nab-paclitaxel + Gemcitabine VS Paricalcitol oral + Nab-paclitaxel + Gemcitabine VS Placebo + Nab-paclitaxel + Gemcitabine | Pancreatic cancer | 1/2 | NCT03520790 | |
| Paricalcitol + Nab-paclitaxel + Gemcitabine + Nivolumab VS Nab-paclitaxel + Gemcitabine + Nivolumab | Pancreatic cancer | Early 1 | NCT03519308 | ||
| Paricalcitol + Nab-paclitaxel + Gemcitabine + Cisplatin | Pancreatic cancer | 2 | NCT03138720 | ||
| Paricalcitol IV + Nab-paclitaxel + Gemcitabine | Pancreatic cancer | N/A | NCT02030860 | ||
| Paricalcitol + Nab-paclitaxel + Cisplatin + Gemcitabine | Pancreatic cancer | 2 | NCT03415854 | ||
| Paricalcitol IV + Nab-paclitaxel + Cisplatin + Gemcitabine + Nivolumab | Pancreatic cancer | 2 | NCT02754726 | ||
| Nintedanib | Nintedanib monotherapy followed by combination therapy of Nintedanib + Gemcitabine + Nab-Paclitaxel | Pancreatic cancer | 1/2 | NCT02902484 | |
| Nintedanib | Nintedanib + Nab-Paclitaxel VS Placebo + Nab-paclitaxel | Non-small cell lung cancer | 1/2 | NCT03361319 | |
| Metformin | Metformin + Nab-Paclitaxel + Gemcitabine + Dietary supplement | Pancreatic cancer | 1 | NCT02336087 | |
| Hyaluronidase | VCN-01 (genetically modified human adenovirus encoding human PH20 hyaluronidase) + Gemcitabine + Nab-Paclitaxel | Pancreatic cancer | 1 | NCT02045589 | |
| Hyaluronidase | VCN-01+ Nab-Paclitaxel + Gemcitabine VS VCN-01 | Pancreatic cancer | 1 | NCT02045602 | |
| PEGylated Liposomal Doxorubicin (PLD), Doxil®, Caelyx® | |||||
| Nintedanib (BIBF 1120) | Nintedanib + PLD + Carboplatin | Ovarian cancer, or peritoneal cancer | 1 | NCT01314105 | |
| Nintedanib + PLD | Ovarian cancer | Terminated (funding withdrawn due to drug unavailability) | NCT01485874 | ||
| Nintedanib + PLD + Carboplatin | Ovarian cancer | Terminated | NCT01329549 | ||
ECM, extracellular matrix; 5-FU, 5-fluorouracil.